Sep 19 2011
Meda (STO:MEDAA) has acquired exclusive licensing rights to Nalox (treatment of fungal nail infections/nail psoriasis) from Moberg Derma AB. Within a short time span, Meda has established Nalox as the market leader in the Nordic region. The new agreement covers several major European countries, such as Germany, France, the UK, Spain, Austria, the Netherlands and Belgium.
"We continue to strengthen our position in dermatology in Europe. We're looking forward to successful launches in new markets", says Anders Lönner, Meda CEO.